Allarity Therapeutics Files S-3/A Amendment

Ticker: ALLR · Form: S-3/A · Filed: Apr 24, 2026 · CIK: 0001860657

Sentiment: neutral

Topics: registration-statement, amendment, pharmaceuticals

TL;DR

Allarity Therapeutics filed an S-3/A amendment on 4/24/26. Likely preparing for a stock offering.

AI Summary

Allarity Therapeutics, Inc. filed an amendment (S-3/A) on April 24, 2026, to its registration statement. This filing includes an amendment to the S-3 and a consent from their independent registered public accounting firm, Wolf & Company, P.C. The company is located at 24 School St., 2nd Floor, Boston, MA 02108.

Why It Matters

This S-3/A filing indicates that Allarity Therapeutics is updating its registration statement, which is often a precursor to issuing new securities or making other significant financial transactions.

Risk Assessment

Risk Level: medium — Amendments to S-3 registration statements can signal upcoming stock offerings, which may dilute existing shareholders or indicate the company needs capital.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this S-3/A filing?

This filing is an amendment to a registration statement under the Securities Act of 1933, indicating updates or changes to the company's previously filed registration.

Who is the independent registered public accounting firm mentioned?

Wolf & Company, P.C. is the independent registered public accounting firm whose consent is included in the filing.

What is the business address of Allarity Therapeutics, Inc.?

The business address is 24 School St., 2nd Floor, Boston, MA 02108.

What is the CIK number for Allarity Therapeutics, Inc.?

The CIK number for Allarity Therapeutics, Inc. is 0001860657.

What is the SIC code for Allarity Therapeutics, Inc.?

The SIC code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form S-3/A (Form S-3/A) was filed with the SEC on April 24, 2026 regarding Allarity Therapeutics, Inc. (ALLR).

View full filing on EDGAR

View Full Filing

View this S-3/A filing on SEC EDGAR

View on Read The Filing